Pharmaceutical Technology

JULY 14, 2022

Historically, the pharmaceutical industry has failed to meet the needs of this patient population. Most famously, the US passed its Orphan Drug Act in 1983, providing innovators with financial motivation to develop orphan drugs and meet the needs of these forgotten patients. Efforts have been made to change this.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

Digital Pharmacist

MARCH 28, 2024

Educate Your Staff on Parkinson’s Disease Pharmacists are a constant in the lives of patients living with Parkinson’s Disease. Parkinson’s patients and their caregivers are going to be frequent customers at your pharmacy, so it is important for your staff to understand the disease they’re faced with and the medications used to treat it.

Health and Personal Care Stores 68

Health and Personal Care Stores Hospitals 68

pharmaphorum

NOVEMBER 19, 2021

Roche’s oral treatment Evrysdi for the rare genetic disease spinal muscular atrophy (SMA) will be made available on the NHS in England, after NICE reached a three-year access agreement with the company. million price tag make it is the most expensive treatment ever approved for NHS funding.

98

98

Pharmaceutical Technology

FEBRUARY 10, 2023

This is not the first treatment to come with a high price tag. The three agreed on a confidential price, and the TLV determined whether the drug was cost effective for the eligible patient population. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

FDA 105

FDA 105

pharmaphorum

APRIL 20, 2021

According to Novartis, Kesimpta is the first targeted B cell therapy for RMS that can be self-administered at home once a month using an autoinjector, avoiding the need for patients to travel to hospital during the pandemic, and easing the pressure on clinicians. billion by 2028.

Hospitals 110

Hospitals Documentation 110

pharmaphorum

JANUARY 21, 2022

Access to medicines is “one of the most challenging policy areas in every country in the European region” – it’s time to develop a solution that works for everyone. Balancing the incentivisation of innovation against affordable access to revolutionary new medicines is an age-old conundrum in the biopharmaceutical industry. WHO is OMI?

Insurance 52

Insurance Vaccines 52

pharmaphorum

NOVEMBER 16, 2021

NHS patients in England and Wales with drug-resistant epilepsy are in line for access to another treatment option, after NICE recommended routine use of Angelini group company Arvelle Pharma’s Ontozry. The drug was eventually cleared in the EU in April, with the UK giving it a green light in June.

Documentation 96

Documentation 96

pharmaphorum

OCTOBER 21, 2021

As it turned out, Aduhelm (aducanumab) made just $300,000 in the three-month period from July to September, against analysts’ estimates of $12 million, suggesting that few patients are being treated with the $56,000 a year therapy. Biogen reported $1.6 million in sales for the drug in the second quarter.

Insurance 119

Insurance FDA 119

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

APRIL 5, 2023

More than a decade after the first patient was treated with a CAR-T therapy, six therapies relying on the same principles have been approved by the US Food and Drug Administration (FDA) and marketed to thousands of patients. AZ: What is the ISCT doing to tackle supply and access-related obstacles in the CAR-T field?

FDA 59

FDA Immunization 59

pharmaphorum

SEPTEMBER 15, 2020

The huge rise in the use of telemedicine services during lockdown has brought care directly to patients in their homes, while pharma’s communications with healthcare professionals (HCPs) has experienced a similar push to digital channels. Jeremy Richter, Tag. We’re all trying to find ways to automate. About the interviewees.

Communication 118

Communication Documentation Labelling Vaccines 118

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels. Regulated industry learnings.

Communication 91

Communication Insurance Packaging Pharmaceutical Companies 91

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. ICER points to brain swelling and potential bleeding seen in approximately 30% of patients treated with aducanumab. Broad label questioned.

FDA 98

FDA Labelling 98

Roots Analysis

JANUARY 28, 2024

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Hospitals 40

pharmaphorum

NOVEMBER 24, 2021

reSET-O was the first prescription DTx ever to win a breakthrough device designation from the FDA, according to Pear , allowing it to tap into a programme intended to speed up the development and regulatory review of new therapies so they can reach patients sooner. Photo by thom masat on Unsplash.

FDA 58

FDA 58

Pharmaceutical Technology

JUNE 29, 2022

Additionally, pricing and access for rare disease therapies continue to be scrutinized closely. Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet. of the total patient population suffering from rare diseases. Approximately 10.9%

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. The post NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group appeared first on.

Documentation 52

Documentation Communication 52

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA 40

FDA 40

The Checkup by Singlecare

MARCH 21, 2023

It is a personal experience, and access to pain management is a basic right. There are other options available to treat pain that does not improve with hydrocodone-acetaminophen or in patients who experience adverse events. Qdolo (tramadol) Qdolo (tramadol) is an alternative to stronger opioids in certain patients.

Dosage 52

Dosage Controlled Substances Labelling Packaging 52

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. Advanced therapies have changed the treatment landscape for the industry and for patients. However, with a price tag of €1.58

130

130

Pharmaceutical Technology

MARCH 22, 2023

The pharmaceutical industry began using radio frequency identification (RFID) tags in the early 2000s. Pfizer was the first to use the tech, adding RFID tags to track a Viagra (sildenafil) shipment circa 2006. Twenty years ago, the cost of implementing RFID tags and the ecosystem (software) was much more expensive than today.

Labelling 105

Labelling Data Entry Communication FDA 105

pharmaphorum

JUNE 15, 2021

Can the biopharma industry step up again to shatter industry orthodoxy and create new pathways for innovation, access, and affordability? Not surprisingly then, payers feel the pain: increased focus on financial consideration causes friction between pharmacy benefit managers, payers, HCPs and patients. But there is a silver lining.

Vaccines 90

Vaccines 90

The Checkup by Singlecare

MARCH 7, 2024

With long delays in getting appointments and access to Ozempic sometimes limited by shortages , many people look into getting Ozempic online, obtaining prescriptions via telehealth appointments, and buying it from internet pharmacies. Patients typically start on a low dose of 0.25 The right dose is determined over time.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Packaging Insurance Coverage 52

European Pharmaceutical Review

MAY 11, 2023

In this Q&A, Dr Sitra Tauscher-Wisniewski, Vice President of Clinical Development & Analytics of Novartis Gene Therapies elaborated on the key findings and discussed the importance of collaboration in fast-tracking access to gene therapies such as Zolgensma. 1 This is assuming a $1M price tag for all gene therapies.

FDA 72

FDA 72

The Spirit Pharmacist

DECEMBER 2, 2021

Growing Pains and the Access Bottleneck. However, psychedelic assisted therapy is resource intensive and will likely come with a price tag putting it out of reach of many persons that could benefit from such therapies. You can make a donation to the fund or apply to receive its benefits using the links below: Donate and Support.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Coverage Insurance Patient Care 52

Pharmaceutical Technology

JANUARY 27, 2023

Before Cablivi’s approval, patients relied on a combination of plasma exchange plus corticosteroids and immunomodulators as the standard of care (SOC) for treatment. Sanofi’s eligibility requirements follow a similar model to Pfizer’s previous programs, with refunds being dependent on lack of clinical outcome in patients.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

MARCH 9, 2023

In addition to serving as Associate Editor-in-Chief of the IEEE Open Access Journal of Circuits and Systems, she has been an Associate Editor of IEEE Transactions on Biomedical Circuits and Systems since 2008. Other Affiliations: Alison works as a visiting researcher at Imperial College's Institute of Biomedical Engineering.

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

Viseven

FEBRUARY 6, 2023

Patients and healthcare providers strongly require an individual approach for various reasons like time restrictions or personal specifics. The demand for a more personalized patient experience and better service catalyzes tectonic changes. Of course, this could not leave the pharma market unaffected.

Communication 75

Communication 75

pharmaphorum

NOVEMBER 28, 2022

Owkin is committed to unlocking the vast potential held within patient data by developing technologies that overcome the privacy and security challenges that until now impacted research.”. Owkin in particular has bagged some high-profile, high-price tag development deals with the likes of Bristol-Myers Squibb and Sanofi.

Hospitals 71

Hospitals 71

pharmaphorum

OCTOBER 4, 2022

A key part of this initiative was the establishment of the Cancer Moonshot Biobank, which will ask cancer patients to donate biospecimens and associated health information to aid research. The objective is to gather patient biospecimens longitudinally to understand how patients react to treatments and how cancer develops over time.

Documentation 103

Documentation Data Entry HIPAA Insurance 103

European Pharmaceutical Review

DECEMBER 27, 2023

Due to shipping and manufacturing requirements, the time from a patient being included in the CAR T programme to receiving therapy can be several weeks. As a result, many patients waiting for the CAR T cells to be infused will need additional therapy (bridging therapy) against the malignance.

Adverse Reactions 86

Adverse Reactions Immunization Medical Schools Chemotherapy 86

The Social Pharmacist

AUGUST 5, 2022

It hides the data in transit using encryption methods, preventing hackers from accessing it as it travels over the link. If you want patients to refill prescriptions and/or contact you, your pharmacy website needs to comply with HIPAA to secure your sensitive patient data. Adding Social Tags to Your Pharmacy Website.

HIPAA 52

HIPAA Customer Service Insurance Labelling 52

The Social Pharmacist

AUGUST 5, 2022

It hides the data in transit using encryption methods, preventing hackers from accessing it as it travels over the link. If you want patients to refill prescriptions and/or contact you, your pharmacy website needs to comply with HIPAA to secure your sensitive patient data. Adding Social Tags to Your Pharmacy Website.

HIPAA 40

HIPAA Customer Service Insurance Labelling 40

Policy Prescription

APRIL 1, 2022

from licensed pharmacies to American patients. If you don’t have access to The Wall Street Journal, then The Star Democrat, a Maryland paper, published a story accessible for free: Cambridge-based Safe Chain Solutions implicated in massive counterfeit HIV drug scheme.] . [If But its scale is breathtaking.

FDA 40

FDA Documentation 40

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach. compared to a 5.1%

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

Previously, the standard of care for obesity consisted of holistic changes to diet, exercise, and bariatric surgery for eligible patients. However, despite the effectiveness of bariatric surgery, many obese patients are reluctant to undergo surgical procedures, opening the opportunity for a pharmaceutical approach. compared to a 5.1%

Insurance 98

Insurance Labelling Communication FDA 98

Pharma Marketing Network

JUNE 8, 2020

The way we challenge the status quo is to provide a proven blueprint for optimizing well-being through world-class benefits that are affordable, often costing 30-50 percent less and providing easy access through our ecosystem to align benefits advisors. I mean, what’s more local than interaction between the patient and the doctor.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40